Strong Product Pipeline

2005-2010

2003

2004-2005

• INTERCEPT Red Blood Cells

• Recombinant AAT

• EPOMAX

• Recombinant Hemoglobin

• ADVATE

• ALYX

Participating in $10 Billion Total Market Opportunity

• Influenza Vaccine

• Next-Generation IGIV

Over $1 Billion

Total Market

Opportunity

Expected Launch Dates

• BPI/Neuprex

• Vaccines

• NeisVac-C Vaccine

• Aralast

$500 Million –

$1 Billion

• INTERCEPT

Plasma

• Biocompatible Solutions

• New Drug Formulations

• Vaccines

• INTERCEPT Platelets

• Extraneal PD Solution

• Baxter Patient Care System

$100 Million –

$500 Million

• Next-Generation FEIBA

Previous slide

Next slide

Back to first slide

View graphic version